1. Home
  2. NNVC vs ITRM Comparison

NNVC vs ITRM Comparison

Compare NNVC & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NNVC

NanoViricides Inc.

HOLD

Current Price

$1.25

Market Cap

21.2M

Sector

Health Care

ML Signal

HOLD

Logo Iterum Therapeutics plc

ITRM

Iterum Therapeutics plc

HOLD

Current Price

$0.03

Market Cap

24.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NNVC
ITRM
Founded
2005
2015
Country
United States
Ireland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.2M
24.3M
IPO Year
2008
2018

Fundamental Metrics

Financial Performance
Metric
NNVC
ITRM
Price
$1.25
$0.03
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$9.00
AVG Volume (30 Days)
215.0K
115.7M
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
10.00
57.43
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$947.65
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.85
$0.03
52 Week High
$2.23
$1.34

Technical Indicators

Market Signals
Indicator
NNVC
ITRM
Relative Strength Index (RSI) 58.25 26.10
Support Level $1.09 N/A
Resistance Level $1.29 $0.39
Average True Range (ATR) 0.10 0.02
MACD 0.02 -0.01
Stochastic Oscillator 52.69 3.34

Price Performance

Historical Comparison
NNVC
ITRM

About NNVC NanoViricides Inc.

Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

About ITRM Iterum Therapeutics plc

Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Share on Social Networks: